Experienced in Primitive Neuroectodermal Tumor (PNET)

Dr. Edward H. Kaplan

Hematology Oncology | Oncology
City Of Hope Medical Group Of Illinois PLLC
2520 Elisha Ave, 
Zion, IL 
Accepting New Patients
Offers Telehealth
43 Years of Experience
Experienced in Primitive Neuroectodermal Tumor (PNET)
City Of Hope Medical Group Of Illinois PLLC
2520 Elisha Ave, 
Zion, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Edward Kaplan is a Hematologist Oncology specialist and an Oncologist in Zion, Illinois. Dr. Kaplan has been practicing medicine for over 43 years and is rated as an Experienced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Kaplan is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1982
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
Advocate Lutheran General Hospital
Midwestern Region Med Center, Inc
Swedish Hospital
Northwest Community Hospital 1
Northshore University Healthsystem - Evanston Hospital
Languages Spoken
English
Greek
Hebrew
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Network Health
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

CITY OF HOPE MEDICAL GROUP OF ILLINOIS PLLC
2520 Elisha Ave, Zion, IL 60099
Other Locations
CITY OF HOPE MEDICAL GROUP OF ILLINOIS PLLC
9300 Waukegan Rd, Morton Grove, IL 60053

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 3
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)
A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

2 Total Publications

Rapid biomarker testing for improved clinical decision-making in nonsmall cell lung cancer.
Rapid biomarker testing for improved clinical decision-making in nonsmall cell lung cancer.
Journal: MLO: medical laboratory observer
Published: June 29, 2018
Similar Doctors
Rimas V. Lukas
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Rimas V. Lukas
Hematology Oncology | Neurology | Hematology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Rimas V. Lukas
Hematology Oncology | Neurology | Hematology
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
 (39.7 miles away)
312-695-4360
Experience:
23+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rimas Lukas is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Dr. Lukas has been practicing medicine for over 23 years and is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Astrocytoma, Glioma, Glioblastoma, Brain Tumor, and Gastrostomy.

Karan S. Dixit
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Karan S. Dixit
Hematology Oncology | Neurology | Hematology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Karan S. Dixit
Hematology Oncology | Neurology | Hematology
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
 (39.7 miles away)
312-695-4360
Experience:
14+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Karan Dixit is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Dr. Dixit has been practicing medicine for over 14 years and is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Astrocytoma, Glioma, Brain Tumor, Glioblastoma, and Gastrostomy.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Priya U. Kumthekar
Hematology Oncology | Neurology | Hematology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Priya U. Kumthekar
Hematology Oncology | Neurology | Hematology
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
 (39.7 miles away)
312-695-4360
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Priya Kumthekar is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Dr. Kumthekar has been practicing medicine for over 18 years and is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Astrocytoma, Glioblastoma, Brain Tumor, and Glioma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kaplan's expertise for a condition
ConditionClose
    View All 31 Advanced Conditions
    View All 106 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile